[The antiparkinson activity of a new adamantane derivative].
The activity of the new original compound--hydrochloride N-2-(adamantyl) hexamethylenimine (code A-7) synthesized at the Institute of Pharmacology, Russian Academy of Medical Sciences, was studied on models of akinetic-rigid and tremor manifestations of the parkinsonian syndrome. A-7 completely relieves the akinetic-rigid manifestations of the syndrome and surpasses mydantan and L-dopa in antagonism with haloperidol and triftazine. Just as L-dopa, cyclodol, and mydantan, A-7 alleviates reserpine-induced oligokinesis and restores body temperature which is lowered by reserpine. A-7 possesses evident antitremor activity which advantageously distinguishes it from mydantan which failed to demonstrate antagonism with arecoline. A-7 is promising for further study as a potential agent for the treatment of parkinsonism.
Val'dman
E A
EA
Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Voronina
T A
TA
Nerobkova
L N
LN
D000218:Adamantane / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000547:Amantadine / Q000627:therapeutic use; D000818:Animals; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy; D002375:Catalepsy / Q000139:chemically induced / Q000188:drug therapy; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D004347:Drug Interactions; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D051379:Mice; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy; D051381:Rats; D014282:Trihexyphenidyl / Q000627:therapeutic use
D000978:Antiparkinson Agents; C122112:N-(2-adamantyl)hexamethylenimine; D007980:Levodopa; D014282:Trihexyphenidyl; D000547:Amantadine; D000218:Adamantane